Becton, Dickinson and Company
$212.78+$0.10 (0.0%)
Last close · Data as of Nov 20, 2026
- Market cap
- $41.2B
- P/E
- 24.6x
- EV / EBITDA
- 12.1x
- Revenue
- $21.8B
- Net margin
- 7.7%
- ROCE
- 6.4%
Price chart
Technical chartScreen technicals →+42.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +9.8%
- 3M
- +13.4%
- 6M
- +44.8%
- 1Y
- +42.8%
- 5Y
- +11.6%
52-week range
Day change +$0.10 (0.0%) from $213 to $213 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in BDX, bought on each weekday since 2021.
News & filings
What Becton, Dickinson and Company filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthThe price is 25.3% above its 200-day average, and the 50-day average is above the 200-day.
Concerns (1)
- Return on equity of 6.6% against a peer median of 22.2%.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
Read moreShow less
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
- Sector
- Healthcare
- Shares outstanding
- 287.8M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $41.2B
- P/E
- 24.6x
- P/B
- 1.6x
- EV / EBITDA
- 12.1x
- EV / Sales
- 2.7x
- P/S
- 1.9x
- 52-week high
- $218.03
- 52-week low
- $140.71
Profitability
- Operating margin
- 13.7%
- Net margin
- 7.7%
- EBITDA margin
- 22.7%
- ROE
- 6.6%
- ROCE
- 6.4%
- ROA
- 3.0%
- Asset turnover
- 0.39
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $21.8B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 8.2%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 5.0%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -1.6%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $2.7B
Solvency
- Current ratio
- 1.11
- Debt / Equity
- 0.76
- Debt / Assets
- 0.35
- CFO / Net profit
- 2.04
- Cash / Market cap
- 1.6%
Where the revenue went
Of every $100 of FY2025 revenue, $8 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $11.9B |
| Revenue | Gross profit | $9.9B |
| Gross profit | Research and development | $1.3B |
| Gross profit | Selling, general and administrative | $5.3B |
| Gross profit | Other operating expenses | $396.0M |
| Gross profit | Operating income | $3.0B |
| Operating income | Pretax income | $1.9B |
| Operating income | Interest and other expense | $1.1B |
| Pretax income | Tax and other | $203.0M |
| Pretax income | Net income | $1.7B |
Revenue and net profit
Revenue grew 8.2% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $18.9B | $1.8B |
| FY2023 | $19.4B | $1.5B |
| FY2024 | $20.2B | $1.7B |
| FY2025 | $21.8B | $1.7B |
Cash flows
FY2025: $3.4B from operations, $2.7B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $2.6B | $1.7B |
| FY2023 | $3.0B | $2.1B |
| FY2024 | $3.8B | $3.1B |
| FY2025 | $3.4B | $2.7B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $21.8B+8.2%1Y
- EBITDA
- $5.0B+2.8%1Y
- Net profit
- $1.7B-1.6%1Y
- Cash from operations
- $3.4B-9.6%1Y
- Free cash flow
- $2.7B-13.1%1Y
- Revenue CAGR, 3Y
- 5.0%
- Net profit CAGR, 3Y
- -1.9%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $21.8B | $5.0B | $1.7B | $2.7B | 6.6% | +8.2% | -1.6% |
Monthly returns
Month-by-month returns of BDX across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $55.3B |
| Current assets | $9.3B |
| Non-current assets | $46.1B |
| Liabilities | $29.9B |
| Current liabilities | $8.3B |
| Non-current liabilities | $21.6B |
| Equity | $25.4B |
| Paid-in capital | $20.1B |
| Retained earnings | $16.6B |
| Treasury stock | $9.8B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; BDX highlighted.
P/E against peers
BDX trades at 24.6x earnings against a peer median of 38.7x (a 37% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Becton, Dickinson and CompanyBDXthis companyP/E ↓ discount | $41.2B | 24.6x | 1.6x | 6.6% | 12.1x |
| Edwards Lifesciences CorporationEW | $50.4B | 46.9x | 4.9x | 10.4% | 33.2x |
| Cardinal Health, Inc.CAH | $47.2B | 30.3x | -17.0x | -56.1% | 16.7x |
| IDEXX Laboratories, Inc.IDXX | $44.5B | 42.0x | 27.7x | 66.0% | 30.1x |
| Humana Inc.HUM | $42.0B | 35.4x | 2.4x | 6.7% | — |
| Alnylam Pharmaceuticals, Inc.ALNY | $40.5B | 129.2x | 51.4x | 39.8% | 61.6x |
| Agilent Technologies, Inc.A | $39.1B | 30.0x | 5.8x | 19.3% | 22.1x |
| Waters CorporationWAT | $37.0B | 57.5x | 14.4x | 25.1% | 36.7x |
| Zoetis Inc.ZTS | $33.3B | 12.5x | 10.0x | 80.2% | 9.9x |
| Peer median | — | 38.7x | 7.9x | 22.2% | 30.1x |
Year-to-date ROI
BDX since 1 January, against earlier years.
Historical volatility
BDX's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 13.1% |
| FY2023 | 12.5% |
| FY2024 | 14.2% |
| FY2025 | 13.7% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $21.8B |
| Cost of revenueCost Of Revenue | $11.9B |
| Gross profitGross Profit | $9.9B |
| Operating expensesOperating Expense | $6.9B |
| Research and developmentResearch And Development | $1.3B |
| Selling, general and administrativeSelling General And Administration | $5.3B |
| Other operating expensesOther Operating Expenses | $396.0M |
| Total expensesTotal Expenses | $18.9B |
| Operating incomeOperating Income | $3.0B |
| Interest and other | |
| Pretax incomePretax Income | $1.9B |
| TaxTax Provision | $203.0M |
| Net incomeNet Income | $1.7B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $55.3B |
| Current assetsCurrent Assets | $9.3B |
| Non-current assetsTotal Non Current Assets | $46.1B |
| LiabilitiesTotal Liabilities Net Minority Interest | $29.9B |
| Current liabilitiesCurrent Liabilities | $8.3B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $21.6B |
| EquityTotal Equity Gross Minority Interest | $25.4B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $3.4B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $3.4B |
| Net income, continuing operationsNet Income From Continuing Operations | $1.7B |
| Depreciation and amortisationDepreciation And Amortization | $2.5B |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $2.5B |
| Stock-based compensationStock Based Compensation | $258.0M |
| Deferred taxDeferred Tax | -$474.0M |
| Deferred income taxDeferred Income Tax | -$474.0M |
| Operating gains and lossesOperating Gains Losses | $23.0M |
| Gain loss on sale of businessGain Loss On Sale Of Business | $0.00 |
| Pension and employee benefit expensePension And Employee Benefit Expense | $23.0M |
| Change in working capitalChange In Working Capital | -$800.0M |
| Other non-cash itemsOther Non Cash Items | $284.0M |
| Cash from discontinued operating activitiesCash From Discontinued Operating Activities | $0.00 |
| Investing cash flowInvesting Cash Flow | -$818.0M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$818.0M |
| Capital expenditureCapital Expenditure | -$760.0M |
| Capital expenditure (reported)Capital Expenditure Reported | -$760.0M |
| AcquisitionsPurchase Of Business | $0.00 |
| DisposalsSale Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | $0.00 |
| Purchase of investmentsPurchase Of Investment | — |
| Net investment purchases and salesNet Investment Purchase And Sale | $422.0M |
| Other investing changesNet Other Investing Changes | -$480.0M |
| Cash from discontinued investing activitiesCash From Discontinued Investing Activities | — |
| Financing cash flowFinancing Cash Flow | -$3.6B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$3.6B |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | -$1.8B |
| Net debt issuedNet Issuance Payments Of Debt | -$1.3B |
| Net short-term debt issuedNet Short Term Debt Issuance | $455.0M |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | -$1.8B |
| Net long-term debt issuedNet Long Term Debt Issuance | -$1.8B |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | -$1.0B |
| Common stock repurchasedCommon Stock Payments | — |
| Share buybacksRepurchase Of Capital Stock | — |
| Dividends paidCash Dividends Paid | -$1.2B |
| Common dividends paidCommon Stock Dividend Paid | -$1.2B |
| Other financing chargesNet Other Financing Charges | -$87.0M |
| Cash from discontinued financing activitiesCash From Discontinued Financing Activities | — |
| Change in cashChanges In Cash | -$1.0B |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 0.0% |
| Cash at the start of the yearBeginning Cash Position | $1.9B |
| Cash at the end of the yearEnd Cash Position | $851.0M |
| Free cash flowFree Cash Flow | $2.7B |
| Supplemental |
Learn while you research
Academy chapters picked for Becton, Dickinson and Company and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read